Rejection and graft versus host disease are prominent features in small bowel allotransplantation in rats. Cyclosporine treatment of the recipient and irradiation of the donor were used to circumvent these phenomena in the WAG to brown Norway rat model. Irradiation ofthe donor with five or 10 Gy did prevent graft versus host disease but resulted in a more vigorous rejection of small bowel aliografts in untreated recipients (mean (SEM) survival times of 11.5 (0.4) (n=8) and 7*5 (0.9) (n=11) days respectively, versus 16.6 (2.6) days (n=17), p<001 Various experimental studies on the rejection of small bowel allografts have shown that under certain immunological conditions, immunocompetent cells in these grafts can cause graft versus host disease (GVHD).' While the occurrence of this reaction in well defined inbred systems has been conclusively documented, its importance in outbred systems is uncertain. In a previous study we successfully ameliorated GVHD in the WAG to BN rat model using whole body irradiation of the donor with 10 Gy.5 The effectiveness of donor irradiation had been shown previously in a parent to Fl hybrid rat model in which the donors were irradiated with 7, 9.5, and 10 Gy before small bowel transplantation.267 In this study we investigated the effects of combined cyclosporine treatment and donor irradiation because we had evidence that irradiation of the donor leads to accelerated rejection of the graft.5 We wondered whether cyclosporine could reverse this effect. Earlier we found that cyclosporine, used alone, was not effective in consistently producing long term survivors in the WAG to BN donor-host combination.8 In this study we show that the effect of cyclosporine on GVHD is less pronounced than its effect on rejection, as shown earlier by Kirkman.9 In large animal models cyclosporine proved to be less successful than in certain rat strain combinations.'7 Two recent studies in pigs, using ex vivo irradiation of the transplant with 0.5 Gy, a very low dose, combined with cyclosporine therapy of the recipient showed no effect on host survival time compared with cyclosporine monotherapy.'89 Because the immunological problems of large animal models resemble the problems in our WAG to BN rat model, this model is highly suitable for investigating the effect of irradiation combined with cyclosporine treatment.
(n=17), p<001). Cyclosporine treatment of the recipient (25 mg/kg on days 0, 1, 2, 4, and 6 after transplantation) led to a mean (SEM) survival time of 38.3 (8.5) days (n= 10); 20% of the animals developed graft versus host disease. Combined with 5 Gy donor pretreatment, a similar survival was obtained without occurrence of graft versus host disease. However, cyclosporine treatment combined with 10 Gy led to a significant shortening of graft survival (23.1 (6.8) days, n=9). These results suggest that although irradiation is very effective in preventing graft versus Various experimental studies on the rejection of small bowel allografts have shown that under certain immunological conditions, immunocompetent cells in these grafts can cause graft versus host disease (GVHD).' While the occurrence of this reaction in well defined inbred systems has been conclusively documented, its importance in outbred systems is uncertain. In a previous study we successfully ameliorated GVHD in the WAG to BN rat model using whole body irradiation of the donor with 10 Gy.5 The effectiveness of donor irradiation had been shown previously in a parent to Fl hybrid rat model in which the donors were irradiated with 7, 9.5, and 10 Gy before small bowel transplantation.267 In this study we investigated the effects of combined cyclosporine treatment and donor irradiation because we had evidence that irradiation of the donor leads to accelerated rejection of the graft. 5 We wondered whether cyclosporine could reverse this effect. Earlier we found that cyclosporine, used alone, was not effective in consistently producing long term survivors in the WAG to BN donor-host combination. 8 In this study we show that the effect of cyclosporine on GVHD is less pronounced than its effect on rejection, as shown earlier by Kirkman.9 In large animal models cyclosporine proved to be less successful than in certain rat strain combinations.'7 Two recent studies in pigs, using ex vivo irradiation of the transplant with 0.5 Gy, a very low dose, combined with cyclosporine therapy of the recipient showed no effect on host survival time compared with cyclosporine monotherapy.'89 Because the immunological problems of large animal models resemble the problems in our WAG to BN rat model, this model is highly suitable for investigating the effect of irradiation combined with cyclosporine treatment.
Methods

ANIMALS
A fully allogeneic donor-host model was employed by using inbred WAG (RT1u) rats as donors and inbred BN (RTLn) rats as recipients. The rats weighed between 200-350 g.
OPERATIVE PROCEDURES
Donors were fasted for 24 to 48 hours with water ad libitum. All procedures were performed under ether anaesthesia. The method of orthotopic small bowel transplantation has been published recently.5 Briefly, the small bowel was double tied and cut 1 cm distally to the ligament of Treitz and 1-2 cm proximally to the cxcum. The graft was harvested along with the attached vascular pedicles, consisting of the portal vein and the superior mesenteric artery, including an aortic cuff. The graft was flushed via the superior mesenteric artery with 1-2 ml cold Hank's balanced salt solution (HBSS), and stored in cold HBSS while the recipient was prepared. In the recipient, the infrarenal aorta and inferior caval vein were isolated and end to side anastomoses were performed betwen the graft superior mesenteric artery and the aorta, and the graft portal vein and inferior caval vein, respectively. The host's small bowel was resected and the donor small bowel was anastomosed end to end, proximally with the duodenum, distally with the remnant of the ileum at 1-2 cm from the cxcum. At the end of the operation all rats received a single dose of 20000 IU procaine penicillin G and 20 mg dihydrostreptomycin subcutaneously (Depomycine, Gist-Brocades, The Netherlands). Group 5, irradiation of the donor with 5 Gy in combination with 25 mg/kg of cyclosporine given on days 0, 1, 2, 4, and 6 after transplantation to the recipient, n=9. Group 6, irradiation ofthe donor with 10 Gy in combination with 25 mg/kg of cyclosporine given on days 0, 1, 2, 4, and 6 to the recipient, n=9.
STATISTICS
The survival data were statistically analysed using the Wilcoxon test for group comparison.
Results Table II shows that untreated control rats died after a mean (SEM) survival time of 16.6 (2.6) days. Six of 17 rats showed grade 1-2 symptoms of GVHD for three to four days. In groups 2 and 3, whole body irradiation of the donor with 5 and 10 Gy respectively resulted in a complete absence of GVHD. Surprisingly, the survival times in both groups were significantly shorter than those in the control group (115 (0.4) and 7.5 (0.9) days respectively v 16.6 (2.6) days, p<0-01). The accelerated graft rejection was more vigorous in group 3 than in group 2 (p<002). Rats in group 4 that received 25 mg/kg cyclosporine, survived for a mean (SEM) of 38-3 (8.5) days; two of 10 rats developed clinical symptoms of GVHD.
Pretreatmnent with S Gy in combination with cyclosporine (group 5), produced no significant difference in survival time when compared with group 4 (47.2 (6.8) v 38-3 (8.5) days). However, none of the rats in group 5 showed signs of GVHD or peritonitis. One rat died on day 58 as a result of a late technical complication: stenosis of the proximal intestinal anastomosis. In group 6, irradiation with 10 Gy and cyclosporine therapy resulted in a mean survival time that was significantly shorter than that found in group 4 (23.1 (6.8) v 38.3 (8.5) days, p<0.01). At necropsy, four of the recipients that died in the first week showed symptoms of peritonitis as a result of a vulnerable, glassy transplant. No GVHD was observed in this group. Most rats in groups 4, 5, and 6 that survived more than three to five weeks increased in weight. In comparison with the weight gain observed earlier in a syngeneic (WAG-WAG) study, in which the donor was irradiated with 10 Gy, however, the weight gain was minimal.5
Discussion
This study clearly shows that irradiation of the donor very effectively prevents the occurrence of clinical GVHD. In addition, when GVHD is ameliorated or absent in a fully allogeneic rat model, the acute rejection in untreated recipients is accelerated. This vigorous rejection can be explained by the assumption that irradiation with 10 Gy releases more immunocompetent cells in the peripheral circulation of the recipient than irradiation with 5 Gy. Although we cannot exclude this effect, it is our opinion that the vigorous rejection can only be controlled by cyclosporine therapy when GVHD is not completely abrogated. The mechanisms that are probably responsible for these results have been described in experiments on GVHD in bone marrow transplantation.2021 These studies showed that a GVH reaction can induce a state ofpermanent suppression ofcell mediated and of humoral immune responses.
This functional abnormality of T cells or B cells, or both, is probably related to a maturation defect.20 Therefore the absence of GVHD, with its inherent immunosuppressive effect, is the most plausible explanation for the vigorous rejection that occurred in irradiated donors. From studies in a semiallogeneic parent to an Fl-hybrid rat model it is known that irradiation with 5 Gy, in contrast to 10 Gy, failed to prevent the onset of GVHD.8 Extrapolating these data to our results, we presume that the immunosuppressive effect of subclinical GVHD was responsible for the beneficial effect on the survival time when donors were irradiated with 5 Gy compared with 10 Gy. Moreover, the absence of clinical GVHD may be of clinical importance.
Until now it has been uncertain to what degree, if any, GVHD will complicate human small bowel transplantation. Under the assumption that GVHD will develop after small bowel transplantation, strategies have to be developed to circumvent this complication. In theory, drug treatment or irradiation of the transplant before surgery would be the ideal method to inactivate donor lymphocytes. Practically, irradiation is the easiest procedure and can be performed ex vivo without losing its effect. 7 Obviously, the major problem in small bowel transplantation remains the vigorous rejection process and its suppression. Cyclosporine will be the most important drug in any standard immunosuppressive regimen. This study gives indirect evidence that irradiation of the donor in combination with cyclosporine is useful only when some immunocompetent cells in the graft, capable ofproducing a subclinical GVHD whose immunosuppressive effect is beneficial to the survival ofthe allografts are left. It is necessary to quantify further the donor irradiation dose that will result in the optimal interaction between the occurrence of GVHD and rejection of the graft. 
